There is no currently accepted symptomatic treatment for patients with vascular dementia (VaD), with attempts focusing only on preventative measures.

The purpose of this trial was to explore the therapeutic potential of galantamine beyond Alzheimer’s disease.

After a 4-week, single-blind, placebo run-in period, patients were randomly assigned to galantamine 24 mg/day or placebo for 6 months.